Literature DB >> 3509809

Fluoxetine in the treatment of cataplexy.

N Langdon, J Shindler, J D Parkes, S Bandak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3509809     DOI: 10.1093/sleep/9.2.371

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


× No keyword cloud information.
  15 in total

1.  Narcolepsy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

Review 2.  Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Authors:  Michael J Thorpy
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Recent advances in the treatment of narcolepsy.

Authors:  Nobuhide Hirai; Seiji Nishino
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

Review 4.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 5.  Treatment Options for Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 6.  Genetic association, seasonal infections and autoimmune basis of narcolepsy.

Authors:  Abinav Kumar Singh; Josh Mahlios; Emmanuel Mignot
Journal:  J Autoimmun       Date:  2013-03-13       Impact factor: 7.094

7.  A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine.

Authors:  Y K Wing; S Lee; H F Chiu; C K Ho; C N Chen
Journal:  Postgrad Med J       Date:  1994-01       Impact factor: 2.401

Review 8.  Narcolepsy in the older adult: epidemiology, diagnosis and management.

Authors:  Sangeeta S Chakravorty; David B Rye
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Management of Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

10.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.

Authors:  E Mignot; A Renaud; S Nishino; J Arrigoni; C Guilleminault; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.